Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care
22 Mars 2023 - 1:00PM
Business Wire
-Collaboration will leverage NeoGenomics’ large oncology
diagnostic laboratory and Massive Bio’s proven-at-scale proprietary
artificial intelligence platform to accelerate drug discovery and
optimize patient selection for clinical trials.
Massive Bio, Inc., a private AI-enabled oncology startup that
provides virtual and in-person concierge services for cancer
patients, and NeoGenomics, Inc. (NASDAQ: NEO), a leading provider
of cancer-focused genetic testing services and global oncology
contract research services, today announced a collaboration with
the goal of accelerating the development of new cancer therapies
and ultimately improving the lives of millions of cancer patients
around the world. NeoGenomics will identify patients in real time
who may be eligible for clinical trials based on biomarker status.
Following initial contact and outreach provided directly from
NeoGenomics to the treating physician, Massive Bio will help obtain
patient consent and expediate additional screening and potential
enrollment. This partnership will help to quickly identify patients
eligible for clinical trials and help patients and providers make
an informed decision regarding their potential treatment
avenue.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230322005062/en/
(Graphic: Business Wire)
By combining their respective strengths in biomarker testing,
data analysis, machine learning, and biomarker and genomic
profiling, the collaboration between NeoGenomics and Massive Bio
have achieved a significant milestone in the oncology industry.
"Our mission at Massive Bio is to provide cancer patients with
the best possible care and treatment options,” said Selin Kurnaz,
PhD, CEO and co-founder of Massive Bio. “By partnering with
NeoGenomics, a leading player in the cancer diagnostics industry
that shares Massive Bio’s commitment to advancing cancer research
and improving patient outcomes, we can leverage their expertise in
oncology diagnostics to accelerate the identification of patients
who may be eligible for clinical trials."
“NeoGenomics’ advanced diagnostic tools and U.S. footprint,
combined with Massive Bio's AI capabilities and concierge services
in oncology, will enable us to match patients to clinical trials
faster and more efficiently, resulting in improved outcomes and
reduced costs,” said Vishal Sikri, President of the Advanced
Diagnostics Division of NeoGenomics. “We are thrilled to partner
with Massive Bio to advance precision medicine and improve the
delivery of healthcare services to patients, pharmaceutical
partners, and healthcare providers."
Dr. Arturo Loaiza-Bonilla, MD, co-founder and Chief Medical
Officer of Massive Bio, added, "This collaboration between
NeoGenomics and Massive Bio will enable us to provide patients with
personalized care and support throughout their cancer journey, and
move the needle forward in precision oncology and research."
About Massive Bio
Massive Bio empowers cancer patients to find their best
treatment options, using artificial intelligence to improve
equitable access and precision targeting for clinical trial
matching, drug matching, and drug development. Massive Bio combines
its best-in-class AI platform with technology-enabled services to
remove barriers in clinical trial enrollment, value-based oncology
decisions, and data-driven cancer treatment. The company serves
more than two dozen pharmaceutical companies, contract research
organizations, and hospital networks, and has been awarded an SBIR
contract by the National Cancer Institute. Massive Bio was founded
in 2015 by clinical, technology, and M&A executives, and has a
global presence with nearly 100 people in 12 countries.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus in the world for physicians to help
them diagnose and treat cancer.
NeoGenomics is committed to connecting patients with
life-altering therapies and trials. We believe that, together, with
our partners, we can help patients with cancer today and the next
person diagnosed tomorrow. In carrying out these commitments,
NeoGenomics adheres to all relevant data protection laws, provides
transparency and choice to patients regarding the handling and use
of their data through our Notice of Privacy Practices, and has
invested in leading technologies to ensure the data we maintain is
secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates
CAP-accredited and CLIA-certified laboratories in Fort Myers and
Tampa, Florida; Aliso Viejo and San Diego, California; Research
Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia;
Nashville, Tennessee; and CAP-accredited laboratories in Cambridge,
UK, Rolle, Switzerland, and China. NeoGenomics serves the needs of
pathologists, oncologists, academic centers, hospital systems,
pharmaceutical firms, integrated service delivery networks, and
managed care organizations throughout the United States, and
pharmaceutical firms in Europe and Asia.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230322005062/en/
Massive Bio Erkan Terzi Chief Marketing Officer
eterzi@massivebio.com
NeoGenomics, Inc. Kendra Sweeney VP, Investor Relations &
Communications Kendra.sweeney@neogenomics.com
NeoGenomics (NASDAQ:NEO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
NeoGenomics (NASDAQ:NEO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024